Veracyte Inc (VCYT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veracyte Inc (VCYT) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($44.76 Million) by net assets ($1.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Veracyte Inc to measure how much of total assets are equity-financed.
Veracyte Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Veracyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Veracyte Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Veracyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veracyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fastly, Inc. Class A Common Stock
NASDAQ:FSLY
|
0.029x |
|
All Ring Tech Co Ltd
TWO:6187
|
0.021x |
|
China World Trade Center Co Ltd
SHG:600007
|
0.055x |
|
NH Hoteles
MC:NHH
|
0.219x |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
-0.542x |
|
Fujian Huoju Electronic
SHG:603678
|
-0.005x |
|
Assured Guaranty Ltd
F:DHU
|
0.007x |
|
Black Stone Minerals LP
NYSE:BSM
|
0.058x |
Annual Cash Flow Conversion Efficiency for Veracyte Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Veracyte Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Veracyte Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.18 Billion | $75.10 Million | 0.064x | +50.77% |
| 2023-12-31 | $1.04 Billion | $44.22 Million | 0.042x | +504.37% |
| 2022-12-31 | $1.08 Billion | $7.54 Million | 0.007x | +124.30% |
| 2021-12-31 | $1.10 Billion | $-31.62 Million | -0.029x | -25.09% |
| 2020-12-31 | $421.23 Million | $-9.71 Million | -0.023x | -70.80% |
| 2019-12-31 | $239.46 Million | $-3.23 Million | -0.013x | +92.04% |
| 2018-12-31 | $79.75 Million | $-13.52 Million | -0.170x | +73.61% |
| 2017-12-31 | $37.23 Million | $-23.91 Million | -0.642x | -36.79% |
| 2016-12-31 | $59.58 Million | $-27.98 Million | -0.470x | +10.73% |
| 2015-12-31 | $51.25 Million | $-26.96 Million | -0.526x | +21.22% |
| 2014-12-31 | $41.37 Million | $-27.63 Million | -0.668x | -96.75% |
| 2013-12-31 | $56.44 Million | $-19.16 Million | -0.339x | +76.79% |
| 2012-12-31 | $4.90 Million | $-7.17 Million | -1.462x | +7.76% |
| 2011-12-31 | $8.53 Million | $-13.52 Million | -1.585x | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more